Leading global genomics company to leverage
Rosetta’s commercial infrastructure and expertise in oncology and
pathology
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and
provider of microRNA-based molecular diagnostics and therapeutics,
announces a collaboration with Admera Health, a spin-off from the
clinical services unit of GENEWIZ, Inc., a leading global genomics
company. Focused on personalized medicine, Admera Health is a
molecular diagnostics company that aims to develop and deliver
cost-effective tests that fulfill unmet medical needs, including
clinical molecular oncology diagnostics.
Under the agreement, Rosetta Genomics will leverage its
commercial infrastructure and expertise to market and sell Admera
Health’s tests to oncologists and pathologists. Rosetta Genomics
expects to record initial revenue from these test sales by year
end, with more significant revenue expected to be generated
beginning in 2015 and beyond.
Examples of current tests and services to be marketed by Rosetta
Genomics include:
- PGxOne™ – A pharmacogenomics
test that predicts how patients will respond to drug therapy based
on their personal genetic makeup. Because differences between
individuals can affect drug absorption, metabolism, or activity,
one treatment regimen may work well for one patient while causing
adverse effects for other patients. PGxOne™ provides medically
actionable and clinically relevant data for chemotherapy patients,
allowing physicians to make effective treatment decisions.
- EGFR & KRAS Clinical
Sequencing—DNA sequencing and mutation analysis of EGFR and
KRAS from patient tissue and blood provides clinically relevant
genomic information for physicians, pathologists, and researchers.
EGFR and KRAS sequence analysis of tumor biopsies predicts tumor
response to specific antineoplastic drugs. Most often used in the
treatment of non-small cell lung and colorectal cancers, these
assays are predictive and prognostic indicators for patients on
tyrosine kinase inhibitor drugs, such as Erlotinib (Tarceva®) and
Gefitinib (Iressa™), and anti-EGFR monoclonal antibodies drugs,
such as panitumumab (Vectibix®) and cetuximab (Erbitux®).
“Through this partnership, we are able to engage Rosetta’s
extensive network of physicians and healthcare professionals to
offer greater personalized testing options for patients,” commented
Steve Sun, Chief Executive Officer of Admera Health. “Together, we
will provide physicians with the comprehensive information required
to implement effective, personalized treatment plans swiftly,
bringing the benefit directly to the patient.”
“This collaboration allows us to leverage our commercial
infrastructure and provide our sales representatives with a more
complete solution for pathologists and oncologists while
accelerating the delivery of Admera’s existing rich pipeline of
sequencing-based genomic tests,” stated Kenneth A. Berlin,
President and Chief Executive Officer of Rosetta Genomics.
“Combining Rosetta’s Cancer Origin Test information on tumor type
with Admera’s powerful genomic tests provides physicians with
clinically relevant and medically actionable information from which
to define their treatment protocols, as opposed to using blind
sequencing in settings of anatomic uncertainty. In cases of known
primary cancers, our combined offerings will provide a broader
array of testing options to obtain genomic information of value as
defined in the guidelines of a variety of cancers, such as lung or
colon cancer.”
“This partnership has the potential to greatly accelerate
revenue growth as it should enhance growth in our current,
metastatic cancer segment as well as open up new segments to us in
oncology, ” added Mr. Berlin.
About Admera Health
Admera Health is a molecular diagnostics company focused on
personalized medicine. Utilizing advanced genomic technologies and
bioinformatics analysis, Admera Health delivers cost-effective
clinical diagnostics spanning the continuum of care from its
established, CLIA-certified, CAP-accredited laboratory. Admera
Health is a GENEWIZ company. For more information, please visit
www.admerahealth.com.
About GENEWIZ, Inc.
GENEWIZ, Inc. is a global contract research organization (CRO)
specializing in genomic services, including DNA sequencing, gene
synthesis, molecular biology, and GLP regulatory-compliant
services. GENEWIZ leads the industry in outsourcing partnerships
with pharmaceutical, biotechnology, clinical, academic, and
government institutions. Headquartered in South Plainfield, NJ,
GENEWIZ, Inc. is a privately-held global enterprise with locations
in Boston, MA; Washington, DC Metro; Research Triangle Park, NC;
San Diego, CA; Los Angeles, CA; San Francisco, CA; and Seattle, WA.
International locations include Beijing, China; Suzhou, China;
London, United Kingdom; Langen, Germany; and Tokyo, Japan. For more
information, please visit www.genewiz.com.
About Rosetta Cancer Testing Services
Rosetta Cancer Tests are a series of microRNA-based diagnostic
testing services offered by Rosetta Genomics. The Rosetta Cancer
Origin Test™ accurately identifies the primary tumor type in
primary and metastatic cancer including cancer of unknown or
uncertain primary (CUP). Rosetta Mesothelioma Test™ diagnoses
mesothelioma, a cancer connected to asbestos exposure. The Rosetta
Lung Cancer Test™ accurately identifies the four main subtypes of
lung cancer using small amounts of tumor cells. The Rosetta Kidney
Cancer Test™ accurately classifies the four most common kidney
tumors: clear cell renal cell carcinoma (RCC), papillary RCC,
chromophobe RCC and oncocytoma. Rosetta's assays are designed to
provide objective diagnostic data; it is the treating physician's
responsibility to diagnose and administer the appropriate
treatment. In the U.S. alone, Rosetta Genomics estimates that
200,000 patients a year may benefit from the Rosetta Cancer Origin
Test™, 60,000 from the Rosetta Mesothelioma Test™, 65,000 from the
Rosetta Kidney Cancer Test™ and 226,000 patients from the Rosetta
Lung Cancer Test™. The Company's assays are offered directly by
Rosetta Genomics in the U.S., and through distributors around the
world. For more information, please visit www.rosettagenomics.com.
Parties interested in ordering the test can contact Rosetta
Genomics at (215) 382-9000 ext. 309.
About Rosetta Genomics
Founded in 2000, Rosetta’s integrative research platform
combining bioinformatics and state-of- the-art laboratory processes
has led to the discovery of hundreds of biologically validated
novel human microRNAs. Building on its strong patent position and
proprietary platform technologies, Rosetta is working on the
application of these technologies in the development and
commercialization of a full range of microRNA-based diagnostic
tools and therapeutics. Rosetta currently commercializes a full
range of microRNA-based molecular diagnostics. Rosetta’s cancer
testing services are commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab. For more
information please visit www.rosettagenomics.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects, including without limitation,
statements relating to the expectation that Rosetta will record
initial revenue from these test sales by year end, with more
significant revenue expected to be generated beginning in 2015 and
beyond, and that the collaboration has the potential to greatly
accelerate revenue growth and help Rosetta grow its business in its
current, metastatic cancer segment as well open up new segments in
oncology, constitute forward-looking statements for the purposes of
the safe harbor provisions under The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, including those risks more fully
discussed in the "Risk Factors" section of Rosetta’s Annual Report
on Form 20-F for the year ended December 31, 2013 as filed
with the SEC. In addition, any forward-looking statements represent
Rosetta’s views only as of the date of this release and should not
be relied upon as representing its views as of any subsequent date.
Rosetta does not assume any obligation to update any
forward-looking statements unless required by law.
Admera Health:Brady Millican, 908-222-0533Director of
Business DevelopmentInvestorRelations@admerahealth.comorRosetta
Genomics:Ken Berlin, 609-419-9003President &
CEOinvestors@rosettagenomics.comorInvestors:LHAAnne Marie
Fields, 212-838-3777afields@lhai.comorBruce Voss,
310-691-7100bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2023 to Apr 2024